^
    almost2years
    Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC (clinicaltrials.gov)
    P1/2, N=105, Recruiting, OriCell Therapeutics Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    GPC3 (Glypican 3)
    |
    GPC3 expression
    |
    Ori-C101
    almost2years
    Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC (clinicaltrials.gov)
    P1/2, N=105, Not yet recruiting, OriCell Therapeutics Co., Ltd.
    New P1/2 trial • Metastases
    |
    GPC3 (Glypican 3)
    |
    GPC3 expression
    |
    Ori-C101
    over3years
    [VIRTUAL] An armored GPC3-directed CAR-T for refractory or relapsed hepatocellular carcinoma in China: A phase I trial. (ASCO 2021)
    Patients were pre-conditioned with fludarabine (25̃30 mg/m2) and cyclophosphamide (200̃300 mg/m2) daily for 3 days...Cytokine release syndrome (CRS) was observed in 8 patients, in which 6 at grade 1 or 2 and 2 at grade 4 notably infused with 3 x10e8 both via intravenous route and reversed within 7 days by administering high-dose steroids and tocilizumab... These initial data provide evidence that G3-CAR-ori2 is safe and holds promising antitumor potential, and supports its continuing development in the treatment of r/r GPC3+HCC.
    P1 data • IO biomarker
    |
    GPC3 (Glypican 3)
    |
    fludarabine IV • Actemra IV (tocilizumab) • Ori-C101